TY - JOUR
T1 - Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
AU - Morris, Mitchell
AU - Gershenson, David M.
AU - Wharton, J. Taylor
AU - Copeland, Larry J.
AU - Edwards, Creighton L.
AU - Stringer, C. Allen
N1 - Funding Information:
’ Presented at the annual meeting of the Society of Gynecologic Oncologists, Maui, Hawaii, February 5-9, 1989. ’ To whom correspondence should be sent. Supported by American Cancer Society Award 86-529.
PY - 1989/9
Y1 - 1989/9
N2 - Thirty patients with recurrent epithelial ovarian carcinoma who underwent secondary tumor-reductive surgery at M. D. Anderson Cancer Center were studied retrospectively. All had been initially treated by primary reductive surgery and postoperative chemotherapy and had a period of clinical remission of at least 6 months thereafter. Ninety percent of patients had grade 2 or 3 tumors. In 17 (57%), residual tumor volume was reduced to less than 2 cm. There were no postoperative deaths, but 40% of patients suffered postoperative morbidity, mostly prolonged ileus. Median survival after second surgery was 16.3-18 months for patients with residual tumor volume less than 2 cm and 13.3 months for those with residual volume greater than 2 cm (nonsignificant). When the second surgery followed the first by less than 18 months, survival was a median of 13.5 months after the second operation as compared with 19 months when the interval was 18 months or longer (nonsignificant). Twenty-two patients received postsurgical chemotherapy; only 11% of those who were evaluable responded. Although secondary tumor-reductive surgery for recurrent ovarian cancer is technically feasible, in the absence of an efficacious second-line medical therapy, its value is limited.
AB - Thirty patients with recurrent epithelial ovarian carcinoma who underwent secondary tumor-reductive surgery at M. D. Anderson Cancer Center were studied retrospectively. All had been initially treated by primary reductive surgery and postoperative chemotherapy and had a period of clinical remission of at least 6 months thereafter. Ninety percent of patients had grade 2 or 3 tumors. In 17 (57%), residual tumor volume was reduced to less than 2 cm. There were no postoperative deaths, but 40% of patients suffered postoperative morbidity, mostly prolonged ileus. Median survival after second surgery was 16.3-18 months for patients with residual tumor volume less than 2 cm and 13.3 months for those with residual volume greater than 2 cm (nonsignificant). When the second surgery followed the first by less than 18 months, survival was a median of 13.5 months after the second operation as compared with 19 months when the interval was 18 months or longer (nonsignificant). Twenty-two patients received postsurgical chemotherapy; only 11% of those who were evaluable responded. Although secondary tumor-reductive surgery for recurrent ovarian cancer is technically feasible, in the absence of an efficacious second-line medical therapy, its value is limited.
UR - http://www.scopus.com/inward/record.url?scp=0024439661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024439661&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(89)90168-6
DO - 10.1016/0090-8258(89)90168-6
M3 - Article
C2 - 2767525
AN - SCOPUS:0024439661
SN - 0090-8258
VL - 34
SP - 334
EP - 338
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -